Debra Zack's most recent trade in Exagen Inc was a trade of 3,241 Common Stock done at an average price of $7.1 . Disclosure was reported to the exchange on March 1, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Exagen Inc | Debra Zack | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.12 per share. | 01 Mar 2022 | 3,241 | 84,259 (0%) | 0% | 7.1 | 23,076 | Common Stock |
Exagen Inc | Debra Zack | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 50,000 | 87,500 (0%) | 0% | 0 | Common Stock | |
Exagen Inc | Debra Zack | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 37,500 | 37,500 (0%) | 0% | 0 | Common Stock | |
Exagen Inc | Debra Zack | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 12,500 | 12,500 | - | - | Stock Option(right to buy) | |
Exagen Inc | Debra Zack | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |